BioCentury
ARTICLE | Clinical News

Genexine HPV vaccine shows Phase II efficacy

June 22, 2016 12:15 AM UTC

Genexine Inc. (KOSDAQ:095700) said interim data from a Korean Phase II trial showed its HPV vaccine GX-188E led to a therapeutic effect in 61% of patients with cervical intraepithelial neoplasia (CIN) after 20 weeks, and 67% after 36 weeks. The study enrolled 72 patients with Grade 3 CIN and HPV type 16/18 infection. Results for the DNA therapeutic vaccine were presented at the European Research Organization on Genital Infection and Neoplasia in Salzburg, Austria.

The company did not respond to inquiries about the trial. ...